|
|
|
|
|
15.09.25 - 12:06
|
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea (GlobeNewswire EN)
|
|
|
MALVERN, Pa., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today executed a licensing agreement with Kwangdong Pharmaceutical, Co., Ltd., (“Kwangdong”) one of the leading pharmaceutical companies in Korea, for the exclusive Korean rights to OCU400—Ocugen's novel modifier gene therapy for retinitis pigmentosa (RP)....
|
|
|
02.09.25 - 13:06
|
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 (GlobeNewswire EN)
|
|
|
MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate in both a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025 in New York, NY and a spotlight panel titled “The FDA Gauntlet: Strategies for a Successful Run at Approval” during Biotech on Tap 2025, September 24-26, 2025 in Munich, Germany....
|
|
|
|
|
|
|
12.08.25 - 21:48
|
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants (GlobeNewswire EN)
|
|
|
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management firm, for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company's common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. ...
|
|
|
|
|
08.08.25 - 23:06
|
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants (GlobeNewswire EN)
|
|
|
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with Janus Henderson Investors, a global asset management firm, to purchase 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant in a registered direct offering. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company's common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. ...
|
|
|
04.08.25 - 15:18
|
Demystifying Ocugen: Insights From 5 Analyst Reviews (Benzinga)
|
|
|
Latest Ratings for OCGN
DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Jun 2021Roth CapitalDowngradesBuyNeutral Jun 2021HC Wainwright & Co.MaintainsBuy
View More Analyst Ratings for OCGN
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.06.25 - 13:33
|
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases (GlobeNewswire EN)
|
|
|
PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (Nasdaq: CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Nasdaq: OCGN) (Ocugen), a clinical-stage company developing regenerative cell therapies for orthopedic diseases, today jointly announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the development of OrthoCellix's NeoCart® technology for the treatment of knee articular cartilage defects and plans to initiate a U.S. Food and Drug Administration (FDA)-endorsed Phase 3 clinical trial for NeoCart®....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
